Regarding treatment, we speculated that FBXO32 was likely to play a role in PDAC initiation and progression as well as reprogramming of the tumor immune microenvironment through regulating cell differentiation, angiogenesis, actin cytoskeleton, and some important signaling pathways, such as PI3K/Akt signaling pathway. This evidence concerns the gene AKT1 and neoplasm.